SBIR/STTR Research Award

Genetically Diverse Embryonic Stem Cell Lines For Reproductive Toxicology

Award identifier a35affbd748aeb809b526103d7e09841f186fb2121ec5676b9e7bc379a860e92Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$99,937

Program and phase

SBIR · Phase I

Award year

2007

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
PREDICTIVE BIOLOGY
Proposal award date
Not reported
Contract end date
Not reported
UEI
F1PNSXJZC269
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Determining the reproductive toxicity risk of compounds is vitally important to ensure the health of the general population. It is a difficult and complex task involving testing in animals. While it is well known that mouse strain background can have a profound effect on phenotype, understanding the role of strain background in toxicity testing remains a tremendous challenge. An in vitro genetic testing system contributes toward this end by offering the advantages of lower cost, higher throughput and no sacrifice of animals in testing. An in vitro genetic system can be a "first tier" testing platform, directing in vivo testing to mouse strains that maximize informativeness and minimize animal use. We propose to develop an in vitro, ES cell based system to assess the impact of genetic background in toxicity testing. ES cells are particularly attractive for this purpose since they can be propagated indefinitely in their pluropotent state while retaining the ability to contribute to all tissues of an animal [3]. In Phase I we will determine the feasibility of this system by establishing ES cell lines from a small number of genetically distinct mouse strains and evaluating them in the Embryonic Stem Cell Test (EST) with a reference compound. In Phase II, additional ES lines will be established and tested with a larger panel of reference compounds, toward the development of a system to define the genetic components of toxicity in the EST. This system will lead to more predictive reproductive toxicity testing by providing a platform to investigate the role of genetic background on toxicity risk. The testing platform will be made commercially available to the pharmaceutical and chemical industries, as well as to academic institutions. We propose to develop a system that can help elucidate the role of genetics in reproductive toxicity testing. The broad and varied genetic backgrounds in the proposed testing system better reflects the genetic diversity of the US population, and may lead to more predictive testing that reduces environmental health risk to the population.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

14 SBIR/STTR records share this UEI (2007–2020). Reported award amounts total $7,478,355. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.